Ceftriaxone

On this page

Quick Reference

RxDrug of choiceBacterial meningitis (empiric), Uncomplicated Gonorrhea, Lyme Borreliosis (neurological).

AltAlternativesCefotaxime (preferred in neonates), Cefepime (if Pseudomonas suspected).

⊘AvoidNeonates <28 days receiving calcium IV; Hyperbilirubinemic neonates; Severe cephalosporin allergy.

DxTest of choiceCulture and Sensitivity (MIC determination).

ScKey scoreChild-Pugh Score (to monitor in combined renal/hepatic failure).

→When to referSuspected ceftriaxone-induced encephalopathy; Refractory sepsis; Complex SJS/TEN reactions.

A versatile, once-daily 3rd-gen cephalosporin essential for meningitis and gonorrhea, but carries a black-box risk for fatal calcium precipitates in neonates.

Ceftriaxone is a cornerstone third-generation [[cephalosporin]] antibiotic distinguished by its broad-spectrum activity against Gram-positive and Gram-negative pathogens and a uniquely long half-life that permits once-daily dosing. It functions by inhibiting bacterial cell wall synthesis through high-affinity binding to penicillin-binding proteins (PBPs), leading to osmotic rupture and cell death. Clinically, it is a first-line agent for life-threatening infections including bacterial [[meningitis]], community-acquired pneumonia, and complicated intra-abdominal infections. Beyond its antimicrobial properties, ceftriaxone modulates central nervous system homeostasis by upregulating glutamate transporters, offering potential neuroprotective benefits. However, its use is strictly limited in neonates due to fatal interactions with calcium-containing solutions and the risk of bilirubin displacement, and clinicians must remain vigilant for biliary pseudolithiasis and neurotoxicity in patients with renal impairment.

Overview and Recommendations

Key Facts

•Ceftriaxone is a parenteral third-generation that provides robust coverage against a wide array of aerobic Gram-negative organisms and many Gram-positive cocci, though it lacks activity against , species, and methicillin-resistant (MRSA). Its molecular structure includes a triazine side chain at the 3-position, which confers a prolonged elimination half-life of 5.8 to 8.7 hours, significantly longer than most other beta-lactams.
•The primary mechanism of action involves the irreversible acylation of transpeptidase enzymes (penicillin-binding proteins, specifically PBP 2 and 3), which prevents the cross-linking of chains essential for bacterial cell wall integrity. This inhibition triggers the activation of endogenous autolysins, resulting in rapid bactericidal activity that is strictly time-dependent, meaning efficacy is maximized when the free drug concentration remains above the minimum inhibitory concentration (fT > MIC) for 40% to 70% of the dosing interval.
•Pharmacokinetic stability is maintained through a unique dual-elimination pathway where approximately 33% to 67% of the drug is excreted unchanged in the urine, while the remainder is secreted into the bile and eventually eliminated in the feces. This compensatory mechanism allows for standard dosing (up to 2 g daily) in patients with isolated renal or hepatic failure without the need for adjustment, provided both organs are not simultaneously severely impaired.
•Non-antimicrobial pharmacologic effects include the potent induction of Excitatory Amino Acid Transporter 2 (EAAT2/GLT-1) in , which enhances the clearance of from the synaptic cleft. This mechanism is currently being investigated for neuroprotection in conditions involving excitotoxicity, such as neuropathic pain, epilepsy, and certain neurodegenerative pathways, although its impact on long-term synaptic plasticity remains a subject of preclinical debate.
•The drug is highly protein-bound (85% to 95%) in a concentration-dependent manner; as plasma levels rise above 300 mcg/mL, the protein-binding sites become saturated, increasing the free (active) fraction of the drug. This non-linear pharmacokinetics means that higher doses (e.g., 2 g) result in a disproportionately higher concentration of free drug available for tissue penetration, which is particularly relevant in the treatment of central nervous system infections.

Clinical Use

•Suspect bacterial in patients presenting with fever, headache, and nuchal rigidity; initiate ceftriaxone 2 g IV every 12 hours (or 100 mg/kg/day in pediatrics) to ensure therapeutic cerebrospinal fluid (CSF) concentrations, which reach 5.6 to 6.4 mcg/mL in the presence of inflamed meninges.
•Order ceftriaxone 1 g to 2 g IV once daily for the management of (CAP), typically in combination with a macrolide like to cover atypical pathogens. While 2 g is common for severe presentations, clinical evidence suggests 1 g daily is non-inferior for most hospitalized patients with CAP.
•Administer a single intramuscular dose of 500 mg for the treatment of uncomplicated urogenital, rectal, or pharyngeal . Note that clinical guidelines have shifted toward this higher dose (and sometimes 1 g in patients weighing ≥150 kg) to overcome increasing minimum inhibitory concentrations (MICs) globally.
•Utilize ceftriaxone 2 g IV every 24 hours as a primary component of empiric therapy for or when the source is suspected to be the urinary or respiratory tract. Pre-hospital administration by emergency medical services has been shown to significantly reduce the time to first antibiotic dose without increasing adverse event rates.
•Employ a synergistic combination of 2 g every 4 hours plus ceftriaxone 2 g every 12 hours for the treatment of caused by Enterococcus faecalis. This regimen leverages ceftriaxone's ability to saturate PBP 2 and 3, which enhances the binding of ampicillin to PBPs 4 and 5, providing an effective alternative to aminoglycoside-containing regimens.
•Initiate surgical prophylaxis with a single 1 g IV dose administered 0.5 to 2 hours prior to the start of contaminated or potentially contaminated procedures to reduce the risk of postoperative site infections.
•Manage acute gastroesophageal variceal hemorrhage in patients with by administering 1 g IV daily for 2 to 7 days. A short 2-day course has been shown to be non-inferior to longer courses for preventing early rebleeding and infection in this high-risk population.
•Treat complicated skin and skin structure infections (SSSI) with 1 g to 2 g IV once daily, targeting Streptococcus pyogenes and methicillin-susceptible Staphylococcus aureus (MSSA). For infections confirmed to be MSSA, ensure the dose is at least 2 g daily to achieve optimal target attainment, though remains the preferred agent for MSSA bacteremia.
•Consider ceftriaxone 2 g IV daily for the treatment of neurological or late-stage (Lyme borreliosis). While oral is often sufficient for early localized disease, parenteral ceftriaxone remains the standard for central nervous system involvement or refractory arthritis.
•Add anaerobic coverage, such as 500 mg every 8 hours, when using ceftriaxone for intra-abdominal infections or perforated appendicitis, as ceftriaxone lacks reliable activity against Bacteroides fragilis and other gut anaerobes.
•Monitor for clinical response in patients with or severe shigellosis, where ceftriaxone 1 g to 2 g daily (or 50 mg/kg in children) is a standard parenteral option, though resistance in XDR Shigella strains is an emerging concern.
•Avoid using ceftriaxone as monotherapy for hospital-acquired pneumonia or healthcare-associated infections where or multi-drug resistant Gram-negative rods are suspected; in these cases, broader agents like or are required.

Safety

•Do NOT administer ceftriaxone to neonates (≤28 days) who require calcium-containing intravenous solutions, such as or Lactated Ringer's. Fatal crystalline precipitates of ceftriaxone-calcium can form in the lungs and kidneys; these fatalities have occurred even when different infusion lines and different sites were used.
•Avoid use in premature or hyperbilirubinemic neonates because ceftriaxone competes with bilirubin for albumin binding sites. This displacement can lead to increased free bilirubin levels and subsequent (kernicterus).
•Monitor for biliary "pseudolithiasis" (biliary sludge or stones), particularly in pediatric patients or those receiving high doses for prolonged periods. This occurs due to the precipitation of ceftriaxone-calcium salts in the gallbladder and is typically reversible upon drug discontinuation, though it can occasionally cause symptomatic cholecystitis.
•Screen for a history of severe beta-lactam hypersensitivity before administration. While cross-reactivity with penicillins is low (~1-3%), ceftriaxone is contraindicated in patients with a history of anaphylaxis, SJS/TEN, or other severe reactions to any .
•Discontinue therapy immediately if signs of immune-mediated occur. This rare but potentially fatal complication involves the development of antibodies against the drug-erythrocyte complex; if anemia develops during treatment, ceftriaxone should be stopped until the cause is identified.
•Assess for neurotoxicity, including , myoclonus, and non-convulsive status epilepticus, especially in elderly patients or those with severe renal impairment. These effects are often associated with excessive dosing relative to renal function and typically resolve within days of stopping the drug.
•Evaluate patients for -associated diarrhea (CDAD) if they develop new-onset diarrhea during or up to two months after therapy. Ceftriaxone significantly alters the gut microbiome and is a well-known trigger for C. diff overgrowth.
•Monitor renal function and serum potassium if co-administering with other nephrotoxic agents, although ceftriaxone itself is generally not nephrotoxic. No dose adjustment is needed for isolated renal impairment (CrCl > 10 mL/min) unless the dose exceeds 2 g per day.
•Check for hematologic abnormalities such as eosinophilia (6%), thrombocytosis (5%), or leukopenia (2%), which are generally mild and asymptomatic but may require monitoring during long-term therapy (e.g., for osteomyelitis).
•Ensure that intravenous lines are thoroughly flushed with a compatible fluid (e.g., 0.9% Sodium Chloride) between ceftriaxone and calcium-containing infusions in patients older than 28 days to prevent physical incompatibility and precipitation in the IV tubing.
•Be aware of the sodium content (83 mg or 3.6 mEq per gram of ceftriaxone), which may be clinically significant for patients on strict sodium restriction, such as those with severe or advanced cirrhosis with ascites.
•Avoid ceftriaxone for the treatment of methicillin-susceptible Staphylococcus aureus (MSSA) bloodstream infections if possible; meta-analyses suggest a 57% increase in 30-day all-cause mortality compared to or antistaphylococcal penicillins.
•Instruct patients to report any signs of a secondary infection, such as oral candidiasis or vaginal yeast infections, as the broad-spectrum nature of the drug can lead to fungal overgrowth.
•Use caution when co-administering with vitamin K antagonists (e.g., ), as alterations in gut flora and potential interference with vitamin K metabolism can enhance anticoagulant effects and increase the risk of bleeding.

Board Review — High Yield

•Kernicterus — Ceftriaxone displaces bilirubin from albumin, making it contraindicated in hyperbilirubinemic neonates.
•Biliary Pseudolithiasis — Reversible gallbladder sludge/stones caused by ceftriaxone-calcium precipitation, common in pediatrics.
•Dual Elimination — Excreted via both renal (33-67%) and biliary pathways; no dose adjustment needed for isolated renal or hepatic failure.
•Calcium Incompatibility — Fatal precipitates in lungs/kidneys of neonates if co-administered with IV calcium (e.g., TPN, Ringer's).
•EAAT2 Induction — Non-antimicrobial mechanism involving upregulation of glutamate transporters, providing neuroprotection.
•MSSA Mortality — Associated with higher 30-day mortality (OR 1.57) compared to cefazolin for MSSA bacteremia.
•Gonorrhea Dosing — Current standard is 500 mg IM single dose (up to 1 g if ≥150 kg) due to rising resistance.
•PBP 2/3 — The primary molecular targets for ceftriaxone's bactericidal cell wall inhibition.
•Enterococcus Synergy — Combined with ampicillin to treat E. faecalis endocarditis via PBP saturation.

Deep Dive — Evidence Details

Introduction and Chemical Structure

▸Ceftriaxone is a third-generation cephalosporin with a long half-life allowing for once-daily administration.
▸The drug contains 83 mg (3.6 mEq) of sodium per gram, which must be monitored in sodium-sensitive patients.
▸Increasing resistance in XDR Shigella and ESBL-producing Enterobacteriaceae is challenging its role as a universal empiric agent.

HY High Yield: Ceftriaxone is the only third-generation cephalosporin with significant biliary excretion, contributing to its long half-life and lack of required dose adjustment in renal impairment (unless concomitant hepatic failure is present).

Ceftriaxone — Ceftriaxone, sold under the brand name Rocephin, is a third-generation cephalosporin antibiotic used for the treatment of a number of bacterial infect...Wikipedia ↗

Ceftriaxone is a pivotal third-generation antibiotic characterized by its broad-spectrum activity and unique pharmacokinetic profile, most notably its long half-life that permits once-daily dosing [label]. It functions as a cell-wall synthesis inhibitor, providing robust coverage against a wide array of Gram-positive and Gram-negative pathogens [label]. Its clinical utility is underscored by its status as a cornerstone therapy for life-threatening infections, including bacterial , , and complicated intra-abdominal infections [label].

Chemical Identity and Composition

Chemically, ceftriaxone sodium is a sterile, semisynthetic disodium salt with the molecular formula C18H16N8Na2O7S3•3.5H2O and a calculated molecular weight of 661.60 [label]. The molecule is defined as (6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-(O-methyloxime), disodium salt, sesquaterhydrate [label]. It exists as a white to yellowish-orange crystalline powder that is readily soluble in water [label].

When supplied as a frozen, iso-osmotic solution in dextrose, the pH of thawed solutions ranges from 6.0 to 8.0 [label]. Each gram of ceftriaxone activity contains approximately 83 mg (3.6 mEq) of sodium, a critical consideration for patients requiring strict sodium restriction [label].

Clinical Significance and Resistance

Ceftriaxone is a mainstay in the empiric of central nervous system infections, such as brain abscesses and meningitis, due to its excellent cerebrospinal fluid penetration ^[2]^C4^[4]^C4. However, its widespread use has facilitated the emergence of extensively drug-resistant (XDR) pathogens. For instance, XDR Shigella species now demonstrate resistance to ceftriaxone, , and , complicating the management of severe diarrheal illness ^[6]^B2c. Furthermore, the rise of invasive extended-spectrum (ESBL)-producing Escherichia coli and Klebsiella pneumoniae in neonatal populations necessitates rigorous susceptibility monitoring to ensure therapeutic success ^[7]^B2c^[8]^B2c.

Pearl: Ceftriaxone's triazine side chain at the 3-position of the cephem nucleus confers its uniquely long half-life, while its broad-spectrum activity makes it a first-line empiric choice for suspected bacterial meningitis [label, 2].

Classification of Cephalosporin Generations

Generation	Representative Agent	Primary Antimicrobial Spectrum
First	Cefazolin	Gram-positive (MSSA, Streptococci)
Second	Cefuroxime	Gram-positive + expanded Gram-negative
Third	Ceftriaxone	Broad Gram-negative + Streptococci
Fourth	Cefepime	Pseudomonas + broad Gram-positive/negative
Fifth	Ceftaroline	MRSA coverage

Mechanism of Action

▸Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to autolysis.
▸Upregulates the glutamate transporter EAAT2 (GLT-1), facilitating synaptic glutamate clearance and providing neuroprotective effects.
▸Modulates the complement C3/C3aR pathway and increases platelet factor 4 (PF4) levels to potentially mitigate neurocognitive decline.

HY High Yield: Ceftriaxone's ability to cross the blood-brain barrier and upregulate GLT-1 makes it a unique candidate for research in neurodegenerative and seizure disorders, distinct from its primary role as an antibiotic.

Inhibition of bacterial cell wall synthesis occurs through the high-affinity binding of the β-lactam ring to essential penicillin-binding proteins (PBPs) [label]. This interaction targets PBPs located on the inner surface of the bacterial cell membrane, which serve as critical enzymes in the final stages of synthesis. By acylating the transpeptidase enzyme, the molecule prevents the cross-linking of peptidoglycan polymer chains, thereby terminating the assembly of the rigid bacterial cell wall [label]. The resulting structural instability leads to osmotic rupture and triggers the activation of endogenous bacterial autolytic enzymes (autolysins), culminating in rapid bactericidal death [label].

Molecular Targets and Antimicrobial Cascade

The efficacy of this third-generation cephalosporin is defined by its stability against a broad range of Gram-negative and Gram-positive β-lactamases [label]. Unlike earlier generations, its molecular configuration allows for enhanced penetration through the outer membrane of Gram-negative bacteria and a high affinity for PBP 2 and PBP 3, which are vital for maintaining cell shape and division.

Non-Antimicrobial Pharmacologic Effects

Beyond its bactericidal role, the molecule exerts significant influence on central nervous system (CNS) homeostasis by modulating transport. It acts as a potent inducer of Excitatory Amino Acid Transporter 2 (EAAT2), also known as GLT-1, primarily within populations ^[12]^D5^[16]^D5.

Glutamate Clearance: Upregulation of EAAT2 expression increases the rate of glutamate reuptake from the synaptic cleft, protecting neurons from excitotoxicity ^[12]^D5^[18]^D5.
Neuroprotection: In models of neuropathic pain and epilepsy, this enhancement of GLT-1 function restores glutamate homeostasis and reduces neuronal hyper-excitability ^[13]^D5^[18]^D5.
Synaptic Plasticity: Chronic administration may influence long-term synaptic potentiation (LTP); however, evidence suggests this may involve a weakening of N-Methyl-D-aspartate receptor (NMDAR)-dependent signaling in specific hippocampal circuits ^[11]^D5.

Immunomodulatory and Gut-Brain Axis Interactions

Recent evidence highlights a role in mitigating perioperative neurocognitive disorders (PND) through the modulation of the and systemic inflammatory markers. Perioperative administration is associated with a reduction in serum complement C3 levels and a concomitant increase in platelet factor 4 (PF4), a rejuvenation factor that may mitigate neurocognitive impairment ^[10]^D5. Furthermore, while the drug alters the colonic microbiota, it also induces specific changes in cytokine expression within the colonic mucosa, reflecting a complex interaction with the host immune response ^[14]^D5.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Impact on Synaptic Plasticity	Enhances neuroprotection via GLT-1 upregulation ^[12]^D5^[18]^D5.	Weakens long-term potentiation (LTP) and NMDAR signaling ^[11]^D5.	Preclinical (Level 5)	Potential for cognitive interference in developing CNS despite neuroprotective benefits.

Pearl: Bactericidal activity is driven by irreversible PBP inhibition, but its unique ability to upregulate EAAT2/GLT-1 provides a secondary pharmacologic axis for neuroprotection and glutamate regulation ^[12]^D5^[18]^D5.

Ceftriaxone Molecular Targets and Effects

Target	Mechanism	Clinical Effect
PBPs (1a, 1b, 2, 3)	Inhibition of transpeptidation	Bactericidal cell wall lysis [label]
EAAT2 / GLT-1	Increased protein expression	Reduced glutamate excitotoxicity ^[12]^D5^[18]^D5
Complement C3	Reduction in serum levels	Prevention of neuroinflammation ^[10]^D5
PF4	Increased systemic levels	Mitigation of neurocognitive impairment ^[10]^D5

Pharmacokinetics (LADME)

▸Ceftriaxone exhibits a long half-life (5.8–8.7 hours) and high protein binding (85–95%), supporting once-daily dosing.
▸Elimination is balanced between renal (33–67%) and biliary routes, allowing for stable PK in single-organ dysfunction.
▸CSF penetration is highly efficient in the presence of meningeal inflammation, reaching levels well above the MIC for common pathogens.

HY High Yield: Ceftriaxone concentrations in the bile can be 10–100 times higher than in the plasma, which can lead to the formation of biliary sludge or 'pseudolithiasis' in susceptible patients [label, 29].

Intravenous infusion over 30 minutes achieves peak plasma concentrations of 151 mcg/mL for a 1 g dose and 257 mcg/mL for a 2 g dose [label]. Unlike many other cephalosporins, this agent exhibits a prolonged elimination half-life of 5.8 to 8.7 hours in healthy adults, which facilitates once-daily dosing for most systemic infections [label]. Multiple-dose regimens (0.5 to 2 g every 12–24 hours) result in a modest accumulation of 15% to 36% above single-dose values [label].

Distribution and Protein Binding

Reversible binding to human plasma proteins is concentration-dependent, creating a non-linear pharmacokinetic profile at high doses. Binding decreases from 95% at concentrations below 25 mcg/mL to 85% at 300 mcg/mL [label]. This saturation of binding sites increases the free fraction of the drug as the dose rises, which in turn increases the apparent volume of distribution (5.8 to 13.5 L) and plasma clearance [label].

Therapeutic concentrations are achieved in diverse tissues, including the gallbladder, lungs, and bone. Following a 2 g dose, the drug effectively penetrates cortical and cancellous bone to maintain levels above common MICs ^[30]^C4. It readily crosses the blood-placenta barrier [label]. In the setting of inflamed meninges, such as in , CSF concentrations reach 5.6 to 6.4 mcg/mL after doses of 50–75 mg/kg, representing significant penetration compared to non-inflamed states [label, 25].

Metabolism and Dual Elimination

Biliary secretion and renal excretion serve as the two primary elimination pathways, providing a compensatory mechanism in the event of single-organ failure. Approximately 33% to 67% of a dose is excreted unchanged in the urine [label]. The remainder is secreted into the bile, where it reaches exceptionally high concentrations—up to 898 mcg/mL in the cystic duct—before being reduced to microbiologically inactive compounds by gut flora in the feces [label, 21]. Because of this dual exit strategy, the total plasma clearance remains relatively stable at 0.58 to 1.45 L/hour [label].

Pharmacokinetics in Special Populations

Renal and hepatic impairments do not necessitate dose adjustments for regimens up to 2 g per day, as the alternative clearance pathway compensates for the deficit [label, 22]. In patients with severe renal impairment (CrCl 5–15 mL/min), the half-life extends to approximately 15.7 hours, yet systemic accumulation remains within safe thresholds [label]. Hemodialysis does not significantly remove the drug; therefore, supplemental dosing after dialysis is generally unnecessary [label]. In pediatric patients with meningitis, the half-life is shorter (~4.3 to 4.6 hours) and the volume of distribution is higher (338 to 373 mL/kg) compared to adults, necessitating higher mg/kg dosing [label, 23].

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Dosing in Cirrhosis	Standard dosing up to 2 g/day is safe [label].	PK may be significantly altered by and shunting, requiring monitoring ^[22]^B2a.	Moderate	Clinical vigilance in C.
CSF Penetration	Reliable for meningitis at 2 g BID ^[25]^A1b.	Variability in CSF uptake may lead to subtherapeutic levels in some ALS/CNS models ^[24]^B2b^[32]^C4.	Low	Higher doses (4 g/day) preferred for CNS.

Pearl: The dual renal and biliary excretion of ceftriaxone eliminates the need for dose adjustment in isolated renal or hepatic failure, provided the total daily dose does not exceed 2 g [label, 22].

Average Pharmacokinetic Parameters in Adults

Parameter	Healthy Adults	Renal Impairment (CrCl <15 mL/min)	Hepatic Disease
Elimination Half-life (hr)	5.8–8.7	14.7–15.7	8.8
Plasma Clearance (L/hr)	0.58–1.45	0.56–0.65	1.1
Volume of Distribution (L)	5.8–13.5	12.5–13.7	13.6
Urinary Excretion (%)	33–67	Reduced	Variable

Pharmacodynamics

▸Bactericidal activity depends on the time free drug concentrations remain above the MIC ($fT > MIC$), requiring 40-70% of the dosing interval for optimal effect.
▸Plasma protein binding is high (85-95%) and saturable, leading to a higher free drug fraction as total plasma concentrations exceed 300 mcg/mL.
▸Ceftriaxone is associated with increased 30-day mortality in MSSA bloodstream infections compared to standard-of-care beta-lactams (OR 1.57).

HY High Yield: The key pharmacodynamic parameter for ceftriaxone is **$fT > MIC$**. Because it lacks a significant post-antibiotic effect against Gram-negative bacilli, maintaining the dosing interval is more critical than achieving high peak concentrations.

! Warning: Meta-analysis data indicates that ceftriaxone is inferior to cefazolin for MSSA bacteremia, with a significantly higher risk of short-term mortality [41].

Bactericidal efficacy is primarily driven by the duration that free serum concentrations remain above the minimum inhibitory concentration ($fT > MIC$) ^[34]^D5^[37]^B2c. As a time-dependent antibiotic, this agent requires maintaining levels above the MIC for at least 40% to 70% of the dosing interval to optimize clinical cure and prevent the emergence of resistance ^[34]^D5^[37]^B2c. Unlike concentration-dependent agents, increasing the peak concentration ($C_{max}$) beyond a certain threshold does not significantly enhance the rate or extent of bacterial killing ^[37]^B2c.

Protein Binding and Free Fraction

High plasma protein binding, ranging from 85% to 95%, significantly influences the pharmacodynamic profile by limiting the fraction of free, active drug available for tissue distribution [label]. This binding is saturable and concentration-dependent; as plasma levels exceed 300 mcg/mL, the bound fraction decreases to 85%, which increases the free drug fraction and potentially enhances initial tissue penetration [label]. This saturation effect is clinically relevant during high-dose therapy (e.g., 2 g IV), where the free drug concentration is disproportionately higher than at lower doses [label].

Tissue-Specific Pharmacodynamics

Pharmacodynamic targets are readily achieved in highly vascularized tissues and specific compartments like the biliary tract and inflamed meninges. Average concentrations reach 581–898 mcg/mL in the bile 1–3 hours after a 1 g IV dose, which is significantly higher than concurrent plasma levels (62.1 mcg/mL) [label]. In pediatric patients with inflamed meninges, CSF concentrations reach 5.6 to 6.4 mcg/mL following doses of 50–75 mg/kg, maintaining levels well above the MIC for common pathogens like S. pneumoniae and N. meningitidis throughout the 24-hour dosing interval [label]. However, pharyngeal infections present a unique challenge; suboptimal antibiotic efficacy in pharyngeal tissues may facilitate the selection of resistant Neisseria gonorrhoeae strains ^[42]^B2c.

Clinical Outcomes and Mortality Risks

Clinical pharmacodynamic success varies by pathogen, with notable limitations in treating certain Gram-positive infections. In methicillin-susceptible Staphylococcus aureus (MSSA) bloodstream infections, the use of this agent is associated with increased 30-day all-cause mortality compared to standard-of-care antistaphylococcal penicillins or cefazolin (OR 1.57, 95% CI 1.15-2.14); NNH not calculable from reported data ^[41]^B2a. This suggests that while the $fT > MIC$ target may be met, the intrinsic activity against MSSA may be inferior to narrower-spectrum alternatives ^[41]^B2a.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Use in MSSA Bacteremia	Avoid; associated with higher mortality ^[41]^B2a.	Use for convenience of once-daily dosing ^[41]^B2a.	Moderate	Cefazolin or Nafcillin remain the preferred agents for MSSA-BSI.
Gonorrhea Dosing	Single 1 g IM dose is recommended ^[36]^A1b.	Lower doses (e.g., 250–500 mg) were historically used.	Strong	Higher doses are now required to overcome increasing MICs ^[33]^A1b^[36]^A1b.

Pearl: Bactericidal activity is strictly time-dependent ($fT > MIC$), but clinicians should avoid its use in MSSA bloodstream infections due to a significantly increased risk of 30-day mortality compared to cefazolin (OR 1.57) ^[41]^B2a.

Ceftriaxone Pharmacodynamic Targets by Site

Compartment	Typical Concentration	PD Significance
Plasma (1g IV at 24h)	9 mcg/mL	Maintains levels above MIC for most susceptible Gram-negatives [label].
Bile (1g IV)	581–898 mcg/mL	High biliary excretion ensures efficacy in cholecystitis [label].
CSF (Inflamed)	5.6–6.4 mcg/mL	Exceeds MIC for major meningitis pathogens in pediatrics [label].
Gallbladder Wall	78.2 mcg/gm	Therapeutic levels achieved for localized infection [label].

Indications and Clinical Use

▸Primary indication for community-acquired pneumonia, bacterial meningitis, and complicated urinary tract infections.
▸Standard of care for uncomplicated gonorrhea, though dosing has shifted from 250 mg to 500 mg–1 g IM to address resistance.
▸Effective prophylactic agent for surgical procedures, OHCA survivors, and cirrhotic patients with GI bleeds.

HY High Yield: Ceftriaxone has NO activity against Chlamydia trachomatis; always add a macrolide or tetracycline when treating pelvic inflammatory disease (PID) [label].

! Warning: Avoid use in neonates (≤28 days) requiring calcium-containing IV solutions due to the risk of fatal ceftriaxone-calcium precipitates [label].

Empiric coverage for community-acquired pneumonia (CAP) and bacterial meningitis relies on the drug's high central nervous system penetration and broad-spectrum activity against common pathogens. Per the FDA label, it is indicated for lower respiratory tract infections caused by S. pneumoniae, S. aureus, H. influenzae, and K. pneumoniae [label]. For hospitalized adults with mild-to-moderate CAP, combination therapy with a β-lactam plus a macrolide is a first-line recommendation alongside respiratory fluoroquinolone monotherapy ^[44]^A1a. In bacterial meningitis, it provides critical coverage against H. influenzae, N. meningitidis, and S. pneumoniae [label].

Sexually Transmitted and Infections

of uncomplicated urogenital gonorrhea typically utilizes a single intramuscular dose, with the FDA label specifying 250 mg [label], while newer international guidelines often recommend 500 mg or 1 g to combat increasing resistance ^[33]^A1b^[36]^A1b^[49]^A1b. It remains a primary comparator in trials for emerging agents like zoliflodacin and gepotidacin ^[33]^A1b^[49]^A1b. Beyond gonorrhea, it serves as an effective substitute for parenteral penicillin in treating various stages of syphilis, particularly for patients with penicillin allergies or poor tolerance ^[45]^B2a. In pediatric populations, intravenous administration is a standard treatment for shigellosis ^[37]^B2c.

Sepsis and Prophylactic Applications

Pre-hospital administration of 2 g IV by paramedics in suspected sepsis cases significantly expedites care, reducing the time to first antibiotic by a median of 108 minutes (95% CI 34–170; p < 0.01) ^[50]^A1b. Prophylactic use is also established in several specialized clinical scenarios:

Surgical Prophylaxis: A single 1 g dose administered 0.5 to 2 hours preoperatively reduces postoperative infection rates in contaminated or potentially contaminated procedures [label].
Cardiac Arrest: Prophylactic administration of 2 g every 12 hours for 3 days reduces the incidence of early-onset pneumonia in comatose survivors of out-of-hospital cardiac arrest (OHCA) ^[47]^A1b. (NNT not calculable from reported data).
Cirrhosis: In patients with A cirrhosis and upper gastrointestinal bleeding, a 72-hour course is the standard of care to prevent day-5 infections ^[52]^A1b.

Skin, Bone, and Intra-abdominal Infections

Treatment of complicated skin and skin structure infections (SSSI) involves doses of 1 g to 2 g once daily, targeting organisms such as S. pyogenes and methicillin-susceptible S. aureus [label]. Network meta-analyses rank it as a highly effective option for managing and ^[43]^A1a. For intra-abdominal infections, it is frequently combined with anaerobic coverage, as most strains of B. fragilis are susceptible but C. difficile is typically resistant [label]. In neurosurgery, it is utilized as standard postsurgical management, sometimes in combination with clindamycin to mitigate neuronal damage and inflammation ^[48]^A1b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Stroke Prophylaxis	Preventive use in acute stroke to reduce pneumonia (PRECIOUS trial) ^[51]^A1b^[53]^B2b.	No significant improvement in 90-day functional outcomes ^[51]^A1b.	Moderate	Routine use in stroke is not universally recommended.
Gonorrhea Dosing	250 mg IM single dose as per older labels [label].	500 mg to 1 g IM single dose to address resistance ^[33]^A1b^[36]^A1b.	High	Clinical practice has shifted toward higher doses.

Pearl: A single 1 g to 2 g daily dose provides effective coverage for most community-acquired infections, but it must be supplemented with anti-chlamydial or anaerobic agents when those pathogens are suspected [label, 33].

FDA-Approved Adult Dosing Regimens

Infection Type	Recommended Dosage	Frequency
Most Infections	1 g to 2 g	Once daily (or divided BID)
Uncomplicated Gonorrhea	250 mg	Single IM dose
Surgical Prophylaxis	1 g	Single dose (0.5–2h pre-op)
Meningitis	100 mg/kg (Max 4 g)	Divided every 12 hours
Skin/Skin Structure	1 g to 2 g	Once daily

Dose and Administration

▸Ceftriaxone must never be mixed or co-administered with calcium-containing IV fluids (e.g., Lactated Ringer's) due to the risk of precipitation.
▸The standard adult dose is 1–2 g daily, but MSSA infections require 2–4 g daily for optimal target attainment.
▸Neonates with hyperbilirubinemia or those requiring calcium infusions should not receive ceftriaxone.

! Warning: Fatal ceftriaxone-calcium precipitates in the lungs and kidneys have been reported in neonates; avoid all concurrent calcium-containing IV products in this population [label].

HY High Yield: For gonorrhea, the current standard is a single 500 mg IM dose. Always add coverage for Chlamydia if not ruled out, as ceftriaxone is ineffective against it [label, 56].

Intravenous administration requires strict avoidance of calcium-containing diluents, such as Lactated Ringer’s or Hartmann’s solution, to prevent the formation of life-threatening ceftriaxone-calcium precipitates [label]. This incompatibility extends to the simultaneous administration of any calcium-containing IV solutions, including parenteral nutrition, via a Y-site [label]. In patients older than neonates, these solutions may be administered sequentially if the infusion lines are thoroughly flushed with a compatible fluid between doses [label]. No dosage adjustment is necessary for patients with isolated hepatic impairment or mild-to-moderate renal impairment [label].

Adult Dosing Regimens

Standard adult therapy typically utilizes 1 to 2 grams administered once daily or in equally divided doses twice daily, depending on infection severity [label]. For infections caused by (MSSA), the dose increases to 2 to 4 grams daily to ensure >90% target attainment [label]. While higher doses are common in clinical practice, a meta-analysis confirms that 1 gram daily is as effective and safe as higher dosing regimens for the treatment of ^[62]^A1a.

In specific acute settings, shorter durations of therapy have proven non-inferior to traditional courses. For patients with acute gastroesophageal variceal hemorrhage, a 2-day course of 1 gram daily is non-inferior to a 5-day course regarding 5-day rebleeding rates ^[55]^A1b. For surgical prophylaxis, a single 1 gram dose should be administered 0.5 to 2 hours before the procedure [label]. Treatment for must continue for at least 10 days to prevent complications [label].

Pediatric and Neonatal Considerations

Neonatal administration is strictly contraindicated in the presence of , particularly in premature infants, due to the risk of bilirubin encephalopathy [label]. Furthermore, ceftriaxone is contraindicated in any neonate requiring (or expected to require) calcium-containing IV infusions because of the high risk of fatal organ precipitation [label].

For pediatric patients (older than 28 days), dosing is weight-based and varies by indication:

Skin and skin structure infections: 50 to 75 mg/kg once daily or divided twice daily (max 2 grams) [label].
Serious miscellaneous infections: 50 to 75 mg/kg divided every 12 hours (max 2 grams) [label].
Bacterial meningitis: An initial loading dose of 100 mg/kg (max 4 grams) is followed by 100 mg/kg/day given once daily or divided every 12 hours (max 4 grams) [label].

Specific Infectious Protocols

Uncomplicated (rectal or pharyngeal) is effectively managed with a single 500 mg intramuscular dose, typically combined with oral 2 g ^[56]^A1b^[57]^A1b. If is a suspected co-pathogen, clinicians must add appropriate antichlamydial coverage, as ceftriaxone lacks activity against this organism [label]. For persistent symptoms attributed to , clinical trials utilize an initial 2-week course of intravenous ceftriaxone before transitioning to oral ^[58]^A1b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Meningitis Duration	Standard 10–14 day course [label].	Shorter courses (≤7 days) may be sufficient for common pathogens ^[61]^A1a.	Moderate	Potential to reduce hospital stay and nosocomial risk.
CAP Dosing	2 grams daily for severe presentation [label].	1 gram daily is non-inferior for most cases ^[62]^A1a.	High	1 gram daily is often sufficient and more cost-effective.
Variceal Prophylaxis	5–7 days of antibiotic coverage ^[55]^A1b.	2 days of ceftriaxone is non-inferior ^[55]^A1b.	Moderate	Shorter courses reduce antibiotic pressure.

Pearl: Ceftriaxone is strictly contraindicated in neonates receiving IV calcium due to fatal precipitation risks, but in older patients, 1 gram daily is often as effective as 2 grams for community-acquired pneumonia [label, 62].

Pediatric Dosing Summary

Indication	Dose	Frequency	Maximum Daily Dose
Skin/Structure	50–75 mg/kg	Once daily or divided q12h	2 grams
Serious Infection	50–75 mg/kg	Divided q12h	2 grams
Meningitis	100 mg/kg	Once daily or divided q12h	4 grams
Acute Otitis Media	50 mg/kg	Single IM dose	1 gram

Dose Modification

▸Standard adult dosing is 1–2 g daily, but MSSA infections require 2–4 g for target attainment.
▸Ceftriaxone is contraindicated in neonates receiving IV calcium due to fatal lung and kidney precipitation risks.
▸No dose adjustment is required for hepatic or mild-to-moderate renal impairment.

! Warning: Never mix ceftriaxone with calcium-containing diluents (e.g., Ringer's or Hartmann's) in the same IV line; in neonates, simultaneous administration is contraindicated regardless of the infusion site [label].

HY High Yield: Ceftriaxone is one of the few cephalosporins that does not require renal dose adjustment until renal failure is severe and accompanied by hepatic impairment [label].

Standard adult dosing ranges from 1 to 2 grams daily, administered as a single dose or in equally divided doses every 12 hours [label]. For (CAP), a meta-analysis of 24 trials confirms that 1 gram daily is as effective as higher dosing regimens ^[62]^A1a. However, infections caused by Staphylococcus aureus (MSSA) require 2 to 4 grams daily to achieve >90% target attainment [label]. In the treatment of uncomplicated , a single intramuscular dose of 500 mg is the established standard, often used in combination with 1 g ^[57]^A1b^[64]^A1b^[56]^A1b.

Pediatric and High-Dose CNS Regimens

Pediatric dosing for serious infections is 50 to 75 mg/kg daily, not to exceed 2 grams [label]. In cases of bacterial , the dose increases to 100 mg/kg (max 4 grams) [label]. High-dose regimens (≥4 g or ≥75 mg/kg) in adults with CNS infections are generally well-tolerated, though clinicians must monitor for neurotoxicity, including and myoclonus ^[66]^B2b. For surgical prophylaxis, a single 1 gram dose administered 0.5 to 2 hours before the procedure is sufficient [label].

Organ Impairment and Critical Care

No dosage adjustment is necessary for patients with isolated hepatic impairment or mild-to-moderate renal impairment [label]. In the intensive care unit, physiological alterations often lead to inadequate antibiotic exposure; therapeutic drug monitoring (TDM) is increasingly utilized to ensure pharmacodynamic targets are met, as standard dosing may only reach targets in 60% of patients ^[65]^D5^[68]^D5.

Neonatal Contraindications and Calcium Interactions

Absolute contraindications apply to hyperbilirubinemic neonates and those requiring calcium-containing intravenous solutions [label]. The risk of fatal ceftriaxone-calcium precipitates in the lungs and kidneys precludes simultaneous administration, even via different lines in neonates [label]. In older patients, sequential administration of ceftriaxone and calcium-containing fluids (e.g., ) is permissible only if lines are thoroughly flushed with a compatible fluid [label].

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
CAP Dosing	1 g daily is sufficient for most patients ^[62]^A1a.	2 g daily preferred for severe or resistant cases [label].	Moderate	1 g reduces cost and potential toxicity.
TDM in ICU	Standard dosing is sufficient for most [label].	Model-based TDM is necessary to avoid subtherapeutic levels ^[65]^D5^[68]^D5.	Emerging	TDM may improve outcomes in septic shock.

Pearl: Ceftriaxone requires no adjustment for renal or hepatic impairment but is strictly contraindicated in neonates receiving calcium-containing fluids due to the risk of fatal precipitation [label].

Pediatric Dosing Summary

Indication	Dose Regimen	Maximum Dose
Skin/Skin Structure	50–75 mg/kg daily (once or divided)	2 g/day
Serious Infections	50–75 mg/kg daily (divided q12h)	2 g/day
Meningitis	100 mg/kg loading, then 100 mg/kg daily	4 g/day

Adverse Effects and Toxicity

▸Ceftriaxone is contraindicated in neonates receiving calcium-containing IV fluids due to the risk of fatal organ precipitation.
▸Biliary pseudolithiasis (sludge) is a reversible but clinically significant adverse effect, particularly in pediatric populations and those on high-dose therapy.
▸Neurotoxicity, including non-convulsive status epilepticus, is a risk in patients with renal failure if doses are not appropriately adjusted.

! Warning: Never dilute ceftriaxone with calcium-containing solutions (e.g., Ringer's or Hartmann's) as this triggers immediate precipitation [label].

HY High Yield: In patients with unexplained neurological decline or altered mental status while on ceftriaxone, consider drug-induced encephalopathy, especially if renal function is impaired [label].

Incidence of adverse reactions remains low, with diarrhea (2.7%) and eosinophilia (6%) representing the most common clinical and laboratory findings, respectively [label]. While generally well-tolerated, the drug's safety profile is uniquely characterized by its potential for calcium-salt precipitation and rare but severe neurotoxicity in patients with renal impairment [label].

Biliary and Renal Precipitation

Ceftriaxone-calcium salts can precipitate in the gallbladder, a phenomenon termed "pseudolithiasis," and in the kidneys [label]. In pediatric populations, a systematic review confirms a significant pooled frequency of ceftriaxone-induced cholelithiasis, which often presents as biliary sludge or stones ^[71]^B2a. While usually reversible upon discontinuation, these precipitates can lead to symptomatic cholecystitis or cholangitis ^[75]^B3b. In a nationwide cohort of pneumonia patients, ceftriaxone use was associated with an increased risk of biliary infections compared to alternative beta-lactams ^[75]^B3b.

Neonatal fatalities have occurred due to crystalline precipitates in the lungs and kidneys when ceftriaxone was co-administered with calcium-containing fluids [label]. This interaction is so potent that at least one neonatal death was reported even when the two agents were administered at different times through different intravenous lines [label]. Consequently, the drug is strictly contraindicated in neonates requiring calcium-containing IV solutions [label].

Hypersensitivity and Cutaneous Reactions

Allergic manifestations range from mild rash (1.7%) and pruritus to life-threatening [label]. Cross-reactivity with penicillins is a critical consideration; clinicians must perform a thorough history of prior beta-lactam allergies before initiation [label]. Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in postmarketing surveillance [label]. Rare instances of acute myocardial ischemia (Kounis syndrome) may also occur as part of a systemic allergic reaction [label].

Neurotoxicity and Hematologic Effects

Serious neurological adverse reactions, including encephalopathy, myoclonus, and non-convulsive status epilepticus, are reported primarily in patients with severe renal impairment who did not receive appropriate dose adjustments [label]. These symptoms are typically reversible and resolve after drug cessation [label].

Hematologic disturbances include thrombocytosis (5.1%) and leukopenia (2.1%) [label]. Immune-mediated is a rare but potentially fatal complication; if a patient develops anemia during therapy, the drug should be discontinued until the etiology is determined [label]. Interestingly, ceftriaxone exhibits a significantly lower rate of drug-induced antibody formation (0.43%) compared to piperacillin/sulbactam (24.02%), representing an absolute risk reduction of 23.59% and an NNH of 4 for piperacillin/sulbactam relative to ceftriaxone for seroconversion ^[73]^B2b.

and Local Effects

Beyond simple diarrhea, -associated diarrhea (CDAD) can occur up to two months after treatment, ranging in severity from mild colitis to fatal toxic megacolon [label]. Local reactions at the injection site, such as pain or induration, occur in 1% of patients [label]. In pediatric emergency settings, non-pharmacological interventions like the Helfer Skin Tap technique or vibration devices (e.g., Buzzy®) are effective in reducing the pain and fear associated with intramuscular injections ^[79]^A1b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Dosing and Toxicity	1 g daily is sufficient for non-CNS infections and minimizes toxicity ^[77]^A1a.	2 g daily may be preferred in severe pneumonia but increases biliary risk ^[74]^B3b^[75]^B3b.	Moderate (Meta-analysis/Cohort)	Dose selection must balance efficacy against the risk of biliary pseudolithiasis.

Pearl: Ceftriaxone-calcium precipitation is a unique, dose-dependent risk that necessitates absolute avoidance of calcium-containing diluents in neonates and careful monitoring for biliary "pseudolithiasis" in pediatric patients [label, 71].

Frequency of Adverse Reactions by System

System	Common (≥1%)	Rare (<1% or Postmarketing)
Hematologic	Eosinophilia (6%), Thrombocytosis (5.1%), Leukopenia (2.1%)	Hemolytic anemia, Neutropenia, Agranulocytosis [label]
Gastrointestinal	Diarrhea (2.7%)	CDAD, Stomatitis, Glossitis, Pseudomembranous colitis [label]
Hepatic	AST elevation (3.1%), ALT elevation (3.3%)	Biliary lithiasis, Jaundice, Gallbladder sludge [label, 71]
Dermatologic	Rash (1.7%)	SJS, TEN, Erythema multiforme, Urticaria [label]
Renal	BUN elevation (1.2%)	Nephrolithiasis, Renal precipitations, Oliguria [label]

Drug Interactions

▸Ceftriaxone is strictly contraindicated with any calcium-containing IV fluids in neonates ≤28 days of age.
▸Probenecid does not affect the plasma clearance or half-life of ceftriaxone.
▸Dual PBP inhibition makes the combination of ampicillin and ceftriaxone a first-line synergy for E. faecalis endocarditis.

! Warning: In patients >28 days, do not use the same infusion line for ceftriaxone and calcium-containing fluids simultaneously; sequential administration requires a thorough saline flush [label].

HY High Yield: The ampicillin + ceftriaxone synergy for E. faecalis is specifically useful in patients at risk for aminoglycoside nephrotoxicity [83].

Fatal precipitation between ceftriaxone and calcium-containing solutions represents the most significant clinical risk, particularly in the neonatal population. In patients ≤28 days of age, the concomitant use of intravenous calcium-containing fluids, including continuous infusions such as parenteral nutrition, is strictly contraindicated [label]. This restriction applies regardless of whether the products are administered through different infusion lines or at different sites, as cases of fatal crystalline deposits in the lungs and kidneys have been documented in this age group [label]. For patients older than 28 days, ceftriaxone and calcium-containing solutions may be administered sequentially, provided the infusion lines are thoroughly flushed with a compatible fluid (e.g., physiological saline) between administrations [label].

Pharmacokinetic Interactions

Unlike most other cephalosporins, the elimination kinetics of this agent are not altered by probenecid [label]. This lack of interaction is attributed to the dual excretion pathway; while 33% to 67% of the dose is cleared renally as unchanged drug, the remainder is secreted in the bile [label]. Although the drug is highly protein-bound (85% to 95%), it generally does not exhibit significant displacement interactions with other highly bound medications in standard clinical practice ^[84]^D5. However, clinicians should monitor for potential enhancements of anticoagulant effects when co-administered with vitamin K antagonists, though this is often secondary to alterations in gut flora rather than direct pharmacokinetic interference.

Therapeutic Synergy

Pharmacodynamic synergy is frequently leveraged in the of and other high-inoculum infections. The combination of or with ceftriaxone is a preferred strategy for Enterococcus faecalis, as ceftriaxone-mediated inhibition of penicillin-binding proteins (PBPs) 2 and 3 facilitates the action of aminopenicillins on PBPs 4 and 5 ^[83]^D5^[85]^D5. Similar synergistic activity has been demonstrated against Listeria monocytogenes ^[81]^C4. In the context of emerging resistance, experimental data show that combining ceftriaxone with the novel β-lactamase inhibitor BLI-489 can restore susceptibility in NDM-producing Klebsiella pneumoniae ^[87]^D5.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Use in E. faecium	Synergistic in vitro against ampicillin-susceptible strains ^[88]^D5.	Synergy may be clinically unattainable due to required concentrations ^[88]^D5.	Moderate	Routine use for E. faecium is not standard compared to E. faecalis.

Pearl: Never co-administer ceftriaxone with calcium-containing IV products in neonates due to the risk of fatal organ precipitation, a risk that persists even if different infusion sites are used [label].

Ceftriaxone Interaction Profile

Interacting Agent	Mechanism	Clinical Management
IV Calcium	Physical precipitation (calcium-ceftriaxone salt)	Contraindicated in neonates; flush lines in older patients [label].
Probenecid	Renal tubular secretion	No dosage adjustment required; no interaction [label].
Aminopenicillins	Synergistic PBP saturation	Preferred combination for E. faecalis endocarditis ^[83]^D5.
BLI-489	β-lactamase inhibition	Potential synergy against NDM-producing K. pneumoniae ^[87]^D5.

Special Populations and Contraindications

▸Absolute contraindication in neonates (≤28 days) receiving IV calcium or with hyperbilirubinemia.
▸No dosage adjustment is required for geriatric patients up to 2 g/day unless dual renal/hepatic failure is present.
▸Pediatric patients are at specific risk for biliary pseudolithiasis and emerging Shigella resistance.

! Warning: Neurological toxicity, including encephalopathy and seizures, can occur particularly in elderly patients or those with renal impairment. Discontinue therapy immediately if these signs manifest [label].

Neonates younger than 28 days represent the most critical risk group due to the potential for fatal ceftriaxone-calcium precipitates in the lungs and kidneys [label]. This contraindication applies even if different infusion lines or different time points are used for administration [label]. Furthermore, the drug is strictly avoided in hyperbilirubinemic or premature neonates because it displaces bilirubin from albumin, significantly increasing the risk of [label].

Pediatrics

Clinical use in children requires monitoring for biliary pseudolithiasis, as ceftriaxone-induced cholelithiasis occurs with a frequency that warrants vigilance during prolonged therapy ^[71]^B2a. While it remains a staple for and perforated appendicitis, emerging resistance in Streptococcus pneumoniae and Shigella sonnei—with resistance rates reaching 88.2% in recent cohorts—necessitates careful susceptibility testing ^[90]^B2c^[92]^B3b. For perforated appendicitis, regimens combining ceftriaxone with are common, though comparative efficacy against piperacillin/tazobactam remains a point of clinical variation ^[91]^B2a.

Pregnancy and

Administration is indicated for managing (PPROM) after 34 weeks to improve maternal and neonatal outcomes ^[1]^A1b. In the context of , ceftriaxone is reserved for complex or neurological presentations in pregnant patients, although recent guidelines suggest may also be considered ^[89]^A1c. Low concentrations are excreted in human milk; while generally considered compatible, clinicians should exercise caution and monitor the infant for diarrhea or candidiasis [label].

Geriatric Use and Neurotoxicity

Patients aged 60 and older typically require no dosage adjustments for regimens up to 2 g per day, as pharmacokinetics remain minimally altered in the absence of severe renal and hepatic impairment [label]. However, this population is more susceptible to neurological adverse reactions, including , myoclonus, and nonconvulsive status epilepticus [label]. Treatment must be discontinued immediately if confusion, somnolence, or altered consciousness develops [label].

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
First-line for Lyme in Pregnancy	Doxycycline is preferred for most situations ^[89]^A1c.	Ceftriaxone is reserved for complex/neurological cases ^[89]^A1c.	Moderate	Shift toward oral doxycycline even in pregnancy.
Post-op Appendicitis	Piperacillin/Tazobactam monotherapy ^[91]^B2a.	Ceftriaxone plus Metronidazole ^[91]^B2a.	Low	Equivalent outcomes in most meta-analyses.

Pearl: Ceftriaxone is strictly contraindicated in neonates receiving any calcium-containing fluids due to the risk of fatal crystalline precipitates in the lungs and kidneys [label].

Contraindications and Absolute Restrictions

Population	Restriction	Rationale
Neonates (≤28 days)	Calcium-containing IV solutions	Fatal ceftriaxone-calcium precipitates [label]
Premature Neonates	All ceftriaxone use	Risk of bilirubin encephalopathy (kernicterus) [label]
Hypersensitivity	Cephalosporin class allergy	Risk of anaphylaxis or severe skin reactions [label]
Corn Allergy	Dextrose-containing bags	Potential for allergic reaction to corn-derived dextrose [label]

References

[1]
Karataş Gezen G, Karaaslan O. “Randomized controlled trial on the effects of different antibiotic regimens in preterm premature rupture of membranes after 34 weeks.” Medicine (2026). PMID: 41650076 ↗
L1RCTCited in: Introduction and Chemical Structure, Special Populations and Contraindications
[2]
Sankar J, Haribabu PPK, Singaravelu Suganya AGK. “Fusobacterium brain abscess as a complication of sinusitis in an immunocompetent adolescent: A case report.” World journal of clinical pediatrics (2026). PMID: 42220957 ↗
L4CASE_REPORTCited in: Introduction and Chemical Structure
[3]
Huang L, Xi Y, Yu M et al.. “Post-endoscopic neurosurgical Candida albicans meningoencephalitis diagnosed by targeted next-generation sequencing: a case report.” Frontiers in medicine (2026). PMID: 42180747 ↗
L4CASE_REPORTCited in: Introduction and Chemical Structure
[4]
Dai L, Zhan W, Huang X et al.. “Refractory multiple brain abscesses caused by Prevotella loescheii and Porphyromonas gingivalis: successful endoscopic lavage and drainage: a case report and review of the literature.” Frontiers in medicine (2026). PMID: 41709890 ↗
L4CASE_REPORTCited in: Introduction and Chemical Structure
[5]
Liu J, Chen Y, Sheng X et al.. “Case Report: Nocardia farcinica infectious arthritis and myositis in an immunocompromised host: diagnostic and management challenges.” Frontiers in medicine (2026). PMID: 41647522 ↗
L4CASE_REPORTCited in: Introduction and Chemical Structure
[6]
Logan N, Birhane MG, McDonald SL et al.. “Emergence of Extensively Drug-Resistant Shigellosis - United States, 2011-2023.” MMWR. Morbidity and mortality weekly report (2026). PMID: 41955161 ↗
L2OTHERCited in: Introduction and Chemical Structure
[7]
Lee CC, Chen CL, Su ST et al.. “Molecular epidemiological characterization of invasive extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates from infants less than 3 months old in East Asia.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41862085 ↗
L2OTHERCited in: Introduction and Chemical Structure
[8]
Kedir BM, Mohammed C, Abdurahman A et al.. “Prevalence and antimicrobial susceptibility profiles of Klebsiella Pneumoniea isolated from cases of bovine mastitis in Maya City, Eastern Hararghe, Ethiopia.” BMC microbiology (2026). PMID: 41792616 ↗
L2OTHERCited in: Introduction and Chemical Structure
[9]
Sharma VD, Singla A, Chaudhary M et al.. “Population Pharmacokinetics of Fixed Dose Combination of Ceftriaxone and Sulbactam in Healthy and Infected Subjects.” AAPS PharmSciTech (2016). PMID: 26644225 ↗
L2RCTCited in: Mechanism of Action
[10]
Wang JL, Ye CH, Teng ZF et al.. “Targeting complement C3/C3aR pathway restores rejuvenation factor PF4 and mitigates neurocognitive impairments in age-related perioperative neurocognitive disorders.” Molecular psychiatry (2025). PMID: 40659841 ↗
L5OTHERCited in: Mechanism of Action
[11]
Postnikova TY, Malkin SL, Zakharova MV et al.. “Ceftriaxone Treatment Weakens Long-Term Synaptic Potentiation in the Hippocampus of Young Rats.” International journal of molecular sciences (2021). PMID: 34445137 ↗
L5OTHERCited in: Mechanism of Action
[12]
Zaitsev AV, Malkin SL, Postnikova TY et al.. “Ceftriaxone Treatment Affects EAAT2 Expression and Glutamatergic Neurotransmission and Exerts a Weak Anticonvulsant Effect in Young Rats.” International journal of molecular sciences (2019). PMID: 31766528 ↗
L5OTHERCited in: Mechanism of Action
[13]
Pottabathini R, Kumar A, Bhatnagar A et al.. “Ameliorative potential of pioglitazone and ceftriaxone alone and in combination in rat model of neuropathic pain: Targeting PPARγ and GLT-1 pathways.” Pharmacological reports : PR (2016). PMID: 26721358 ↗
L5OTHERCited in: Mechanism of Action
[14]
McDermott AJ, Higdon KE, Muraglia R et al.. “The role of Gr-1(+) cells and tumour necrosis factor-α signalling during Clostridium difficile colitis in mice.” Immunology (2015). PMID: 25399934 ↗
L5OTHERCited in: Mechanism of Action
[15]
Maltecca F, Baseggio E, Consolato F et al.. “Purkinje neuron Ca2+ influx reduction rescues ataxia in SCA28 model.” The Journal of clinical investigation (2015). PMID: 25485680 ↗
L5OTHERCited in: Mechanism of Action
[16]
Lee MR, Ruby CL, Hinton DJ et al.. “Striatal adenosine signaling regulates EAAT2 and astrocytic AQP4 expression and alcohol drinking in mice.” Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (2013). PMID: 23032072 ↗
L5OTHERCited in: Mechanism of Action
[17]
Goldstein LH, Gabin A, Fawaz A et al.. “Azithromycin is not associated with QT prolongation in hospitalized patients with community-acquired pneumonia.” Pharmacoepidemiology and drug safety (2015). PMID: 26238864 ↗
L2OTHERCited in: Mechanism of Action
[18]
Liu XX, Yang L, Shao LX et al.. “Endothelial Cdk5 deficit leads to the development of spontaneous epilepsy through CXCL1/CXCR2-mediated reactive astrogliosis.” The Journal of experimental medicine (2020). PMID: 31699822 ↗
L5OTHERCited in: Mechanism of Action
[19]
Lee S, Kim SK, Lee DY et al.. “Pharmacokinetics of a new, orally available ceftriaxone formulation in physical complexation with a cationic analogue of bile acid in rats.” Antimicrobial agents and chemotherapy (2006). PMID: 16641464 ↗
L5OTHERCited in: Mechanism of Action
[20]
Versporten A, Coenen S, Adriaenssens N et al.. “European Surveillance of Antimicrobial Consumption (ESAC): outpatient cephalosporin use in Europe (1997-2009).” The Journal of antimicrobial chemotherapy (2011). PMID: 22096063 ↗
L2OTHERCited in: Mechanism of Action
[21]
Kokai-Kun JF, Roberts T, Coughlin O et al.. “The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies.” Antimicrobial agents and chemotherapy (2017). PMID: 28052855 ↗
L2RCTCited in: Pharmacokinetics (LADME), Dose and Administration
[22]
Comce MH, Weersink RA, Beuers U et al.. “Pharmacokinetics of ceftriaxone, gentamicin, meropenem and vancomycin in liver cirrhosis: a systematic review.” The Journal of antimicrobial chemotherapy (2024). PMID: 39289819 ↗
L2SR_OBSCited in: Pharmacokinetics (LADME)
[23]
Hartman SJF, Brüggemann RJ, Orriëns L et al.. “Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature.” Clinical pharmacokinetics (2020). PMID: 31432468 ↗
L2SR_OBSCited in: Pharmacokinetics (LADME)
[24]
Zhao Y, Cudkowicz ME, Shefner JM et al.. “Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis.” Journal of clinical pharmacology (2014). PMID: 24771634 ↗
L2RCTCited in: Pharmacokinetics (LADME)
[25]
Richards GA, Elliott E, Shaddock EJ et al.. “A comparison of the pharmacokinetics of Aspen Ceftriaxone and Rocephin in community-acquired meningitis.” South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde (2013). PMID: 24300626 ↗
L1RCTCited in: Pharmacokinetics (LADME)
[26]
Kanesaka I, Kong FYS, Vanbaelen T et al.. “An overview of potential combination therapies with ceftriaxone as a treatment for gonorrhoea.” Expert review of anti-infective therapy (2025). PMID: 40374502 ↗
L5REVIEW_NARRATIVECited in: Pharmacokinetics (LADME)
[27]
Derbie A, Mekonnen D, Woldeamanuel Y et al.. “Azithromycin resistant gonococci: a literature review.” Antimicrobial resistance and infection control (2020). PMID: 32811545 ↗
L5REVIEW_NARRATIVECited in: Pharmacokinetics (LADME)
[28]
Kong FYS, Horner P, Unemo M et al.. “Pharmacokinetic considerations regarding the treatment of bacterial sexually transmitted infections with azithromycin: a review.” The Journal of antimicrobial chemotherapy (2019). PMID: 30649333 ↗
L5REVIEW_NARRATIVECited in: Pharmacokinetics (LADME)
[29]
Daudon M, Frochot V, Bazin D et al.. “Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment.” Drugs (2018). PMID: 29264783 ↗
L5REVIEW_NARRATIVECited in: Pharmacokinetics (LADME)
[30]
Gergs U, Clauss T, Ihlefeld D et al.. “Pharmacokinetics of ceftriaxone in plasma and bone of patients undergoing hip or knee surgery.” The Journal of pharmacy and pharmacology (2014). PMID: 24941934 ↗
L4TRIAL_NONRANDOMCited in: Pharmacokinetics (LADME)
[31]
Zhanel GG, Chung P, Adam H et al.. “Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.” Drugs (2014). PMID: 24352909 ↗
L5REVIEW_NARRATIVECited in: Pharmacokinetics (LADME)
[32]
Futagi Y, Ito Y, Nakade J et al.. “Ceftriaxone-induced encephalopathy in a patient with a solitary kidney.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2022). PMID: 35843497 ↗
L4CASE_REPORTCited in: Pharmacokinetics (LADME)
[33]
Luckey A, Balasegaram M, Barbee LA et al.. “Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial.” Lancet (London, England) (2026). PMID: 41391465 ↗
L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
[34]
Srivastava S, Gumbo T. “Systematic and quantitative analyses of hollow fiber model of Mycobacterium abscessus lung disease studies and new dosing recommendations.” Microbiology spectrum (2026). PMID: 42012229 ↗
L5SR_OBSCited in: Pharmacodynamics
[35]
Costa M, Incristi A, Lindsay J et al.. “Effectiveness of antibiotic prophylaxis for ventilator-associated pneumonia in acute brain injury: a systematic review and meta-analysis.” Infection (2026). PMID: 41379388 ↗
L1SR_OBSCited in: Pharmacodynamics, Adverse Effects and Toxicity
[36]
Jiang TT, Zhang XB, Zhao PZ et al.. “App-Based Training Module on Guiding Physicians' Prescription for Antibiotic Treatment of Gonorrhea: Cluster Randomized Controlled Trial.” JMIR mHealth and uHealth (2026). PMID: 41813422 ↗
L1RCTCited in: Pharmacodynamics, Indications and Clinical Use
[37]
Zhang CX, Nuzhat S, Islam MR et al.. “Population Pharmacokinetic and Pharmacodynamic Prediction for Tebipenem Pivoxil Treatment of Pediatric Shigellosis.” Clinical and translational science (2026). PMID: 41454572 ↗
L2RCTCited in: Pharmacodynamics, Indications and Clinical Use, Special Populations and Contraindications
[38]
Tao X, Wang J, Rao J et al.. “Empirical antibiotic therapy for spontaneous intracerebral hemorrhage-associated pneumonia: an ICU-based single-centered retrospective cohort study.” BMC infectious diseases (2025). PMID: 41402792 ↗
L3COHORTCited in: Pharmacodynamics
[39]
Perera V, Wardlow L, Sobhanie MM et al.. “Daptomycin versus beta-lactam based therapy for the treatment of enterococcal endocarditis and other endovascular infections: a retrospective cohort study.” BMC infectious diseases (2025). PMID: 41121008 ↗
L3COHORTCited in: Pharmacodynamics
[40]
Tarigan MB, Saragih RM, Tarigan KA et al.. “Antimicrobial resistance and empirical antibiotic use in diabetic foot infections: A retrospective study from Indonesia.” Narra J (2025). PMID: 41743866 ↗
L4COHORTCited in: Pharmacodynamics
[41]
Maraolo AE, Nobile M, Gentile I. “Ceftriaxone for methicillin-susceptible Staphylococcus aureus bloodstream infections is associated with increased short-term mortality: a systematic review and meta-analysis.” Annals of medicine (2026). PMID: 42112603 ↗
L2SR_OBSCited in: Pharmacodynamics, Adverse Effects and Toxicity
[42]
Visser M, Wolffs PFG, Hoebe CJPA et al.. “Antimicrobial susceptibility patterns of Neisseria gonorrhoeae across anatomical sites within and between individuals in the Netherlands: a retrospective observational study.” The Lancet. Microbe (2026). PMID: 42235568 ↗
L2OTHERCited in: Pharmacodynamics
[43]
Shu Z, Cao J, Li H et al.. “Efficacy and safety of first- and second-line antibiotics for cellulitis and erysipelas: a network meta-analysis of randomized controlled trials.” Archives of dermatological research (2024). PMID: 39240378 ↗
L1SR_MA_RCTCited in: Indications and Clinical Use
[44]
Choi SH, Cesar A, Snow TAC et al.. “Respiratory fluoroquinolone monotherapy vs. β-lactam plus macrolide combination therapy for hospitalized adults with community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials.” International journal of antimicrobial agents (2023). PMID: 37385561 ↗
L1SR_MA_RCTCited in: Indications and Clinical Use
[45]
Liu M, Fan Y, Chen J et al.. “Efficacy and Safety of Treatments for Different Stages of Syphilis: a Systematic Review and Network Meta-Analysis of Randomized Controlled Trials and Observational Studies.” Microbiology spectrum (2022). PMID: 36377935 ↗
L2SR_MA_RCTCited in: Indications and Clinical Use
[46]
Heysell SK, Mpagama SG, Nuwagira E et al.. “Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trial.” The Lancet. Infectious diseases (2026). PMID: 41619753 ↗
L1RCTCited in: Indications and Clinical Use
[47]
Gagnon DJ, Burkholder KM, Weissman AJ et al.. “Ceftriaxone to Prevent Early-Onset Pneumonia in Comatose Patients Following Out-of-Hospital Cardiac Arrest: A Pilot Randomized Controlled Trial and Resistome Assessment (PROTECT).” Chest (2026). PMID: 40885534 ↗
L1RCTCited in: Indications and Clinical Use
[48]
Alam El-Din LW, El-Bassiouny NA, Khedr WM et al.. “The potential impact of clindamycin on neurosurgery patients: a randomized controlled trial.” Inflammopharmacology (2025). PMID: 40549322 ↗
L1RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
[49]
Ross JDC, Wilson J, Workowski KA et al.. “Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study.” Lancet (London, England) (2025). PMID: 40245902 ↗
L1RCTCited in: Indications and Clinical Use
[50]
Cudini D, Smith K, Shao J et al.. “Blood culture collection and administration of intravenous ceftriaxone by paramedics in patients with suspected sepsis (the pass trial).” Emergency medicine Australasia : EMA (2025). PMID: 40098585 ↗
L1RCTCited in: Indications and Clinical Use
[51]
Sluis WM, de Jonge JC, Reinink H et al.. “Impact of central adjudication of the score on the modified Rankin Scale in an international, randomized, acute stroke trial.” European stroke journal (2025). PMID: 39968909 ↗
L1RCTCited in: Indications and Clinical Use
[52]
Gupta A, Agarwal S, Sharma S et al.. “Antibiotic prophylaxis to prevent infection in patients with Child-Pugh A cirrhosis with upper gastrointestinal bleed: an open label randomised controlled trial.” Hepatology international (2025). PMID: 39751759 ↗
L1RCTCited in: Indications and Clinical Use
[53]
Sluis WM, de Jonge JC, Reinink H et al.. “Metoclopramide to Prevent Pneumonia in Patients With Stroke and a Nasogastric Tube: Data From the PRECIOUS Trial.” Stroke (2024). PMID: 39129650 ↗
L2RCTCited in: Indications and Clinical Use
[54]
Zheng T, Wang R, Wu C et al.. “Assessing morinidazole for surgical site infection in class III wounds prevention: a multi-centre, randomized, single-blind, parallel-controlled study.” The Journal of hospital infection (2024). PMID: 38964506 ↗
L1RCTCited in: Indications and Clinical Use
[55]
Lo GH, Yeh JH, Tseng CH et al.. “A Noninferiority Trial Comparing 2 Days vs 5 Days of Terlipressin and Ceftriaxone in Terms of 5-Day Rebleeding for Patients With Acute Gastroesophageal Variceal Hemorrhage.” The American journal of gastroenterology (2024). PMID: 38526204 ↗
L1RCTCited in: Dose and Administration
[56]
Rob F, Klubalová B, Nyčová E et al.. “Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea: a randomized controlled trial.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2020). PMID: 31419483 ↗
L1RCTCited in: Dose and Administration, Dose Modification
[57]
Ross JDC, Brittain C, Cole M et al.. “Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial.” Lancet (London, England) (2019). PMID: 31056291 ↗
L1RCTCited in: Dose and Administration, Dose Modification
[58]
Berende A, ter Hofstede HJ, Vos FJ et al.. “Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease.” The New England journal of medicine (2016). PMID: 27028911 ↗
L1RCTCited in: Dose and Administration
[59]
Westendorp WF, Vermeij JD, Brouwer MC et al.. “Pre-Stroke Use of Beta-Blockers Does Not Lower Post-Stroke Infection Rate: An Exploratory Analysis of the Preventive Antibiotics in Stroke Study.” Cerebrovascular diseases (Basel, Switzerland) (2016). PMID: 27701170 ↗
L2RCTCited in: Dose and Administration
[60]
Vermeij JD, Westendorp WF, Roos YB et al.. “Preventive Ceftriaxone in Patients with Stroke Treated with Intravenous Thrombolysis: Post Hoc Analysis of the Preventive Antibiotics in Stroke Study.” Cerebrovascular diseases (Basel, Switzerland) (2016). PMID: 27336314 ↗
L2RCTCited in: Dose and Administration
[61]
Sudo RYU, Câmara MCC, Kieling SV et al.. “Shorter versus longer duration of antibiotic treatment in children with bacterial meningitis: a systematic review and meta-analysis.” European journal of pediatrics (2024). PMID: 37870611 ↗
L1SR_OBSCited in: Dose and Administration
[62]
Telles JP, Cieslinski J, Gasparetto J et al.. “Efficacy of Ceftriaxone 1 g daily Versus 2 g daily for The Treatment of Community-Acquired Pneumonia: A Systematic Review with Meta-Analysis.” Expert review of anti-infective therapy (2019). PMID: 31179786 ↗
L1SR_OBSCited in: Dose and Administration, Dose Modification
[63]
Jaiswal N, Singh M, Kondel R et al.. “Feasibility and efficacy of gentamicin for treating neonatal sepsis in community-based settings: a systematic review.” World journal of pediatrics : WJP (2016). PMID: 26830306 ↗
L2SR_OBSCited in: Dose and Administration, Dose Modification
[64]
Chen MY, McNulty A, Avery A et al.. “Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): a randomised phase 3 non-inferiority trial.” The Lancet. Infectious diseases (2019). PMID: 31196813 ↗
L1RCTCited in: Dose Modification
[65]
Abdulla A, Ewoldt TMJ, Hunfeld NGM et al.. “The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial.” BMC infectious diseases (2020). PMID: 31952493 ↗
L5TRIAL_NONRANDOMCited in: Dose Modification
[66]
Le Turnier P, Navas D, Garot D et al.. “Tolerability of high-dose ceftriaxone in CNS infections: a prospective multicentre cohort study.” The Journal of antimicrobial chemotherapy (2019). PMID: 30698733 ↗
L2TRIAL_NONRANDOMCited in: Dose Modification
[67]
Usta M, Erkan T, Cokugras FC et al.. “High doses of methylprednisolone in the management of caustic esophageal burns.” Pediatrics (2014). PMID: 24864182 ↗
L1RCTCited in: Dose Modification
[68]
Roggeveen LF, Fleuren LM, Guo T et al.. “Right Dose Right Now: bedside data-driven personalized antibiotic dosing in severe sepsis and septic shock - rationale and design of a multicenter randomized controlled superiority trial.” Trials (2019). PMID: 31852491 ↗
L5TRIAL_NONRANDOMCited in: Dose Modification
[69]
Kang MH, Villablanca JG, Glade Bender JL et al.. “Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study.” BMC research notes (2014). PMID: 24755475 ↗
L4TRIAL_NONRANDOMCited in: Dose Modification
[70]
Jumaah MD, Shuhata MH, Al-Hamndawee DM et al.. “Role of intraoperative antibiotics wound irrigation in reducing surgical site infection following open appendectomy: a randomized controlled trial.” BMC surgery (2025). PMID: 40797247 ↗
L1RCTCited in: Adverse Effects and Toxicity
[71]
Yaseen T, Alam K, Zawiah M et al.. “Ceftriaxone-induced cholelithiasis in pediatrics: pooled frequency, symptoms, and associated factors - systematic review and meta-analysis.” Italian journal of pediatrics (2025). PMID: 41074174 ↗
L2SR_OBSCited in: Adverse Effects and Toxicity, Special Populations and Contraindications
[72]
Hu C, Li G, Chen D et al.. “Antibiotic for community-acquired pneumonia in hospitalized adults: A systematic review and Bayesian network meta-analysis.” Respiratory medicine (2025). PMID: 40404065 ↗
L1SR_OBSCited in: Adverse Effects and Toxicity
[73]
Wang L, Wang L, Wei Z et al.. “Incidence and Clinical Significance of Drug-Induced Antibodies and Hemolytic Anemia Associated With Beta-Lactam Antibiotics: A Prospective Cohort Study.” Pharmacoepidemiology and drug safety (2026). PMID: 41629758 ↗
L2COHORTCited in: Adverse Effects and Toxicity
[74]
Taniguchi J, Aso S, Matsui H et al.. “Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study.” The Journal of antimicrobial chemotherapy (2025). PMID: 40492536 ↗
L3COHORTCited in: Adverse Effects and Toxicity
[75]
Taniguchi J, Aso S, Matsui H et al.. “Association Between Ceftriaxone Use and Biliary Infections in Patients With Pneumonia: A Nationwide Retrospective Cohort Study.” Pharmacoepidemiology and drug safety (2025). PMID: 40398875 ↗
L3COHORTCited in: Adverse Effects and Toxicity
[76]
Häußler SM, Böttcher A, Betz CS et al.. “Acute mastoiditis in pediatric cochlear implant patients - a systematic review.” International journal of pediatric otorhinolaryngology (2025). PMID: 40976090 ↗
L4SR_OBSCited in: Adverse Effects and Toxicity
[77]
Brust-Sisti L, Hu GY, Bridgeman M et al.. “Comparative Efficacy of High- and Low-Dose Ceftriaxone Regimens: A Systematic Review and Meta-Analysis.” The Annals of pharmacotherapy (2026). PMID: 40876848 ↗
L1SR_OBSCited in: Adverse Effects and Toxicity
[78]
de Alencar ACV, Rego AGA, Chady CS et al.. “Alternative antibiotics for the treatment of bacterial meningitis in children: a systematic review of efficacy and safety.” Jornal de pediatria (2025). PMID: 40456280 ↗
L1SR_OBSCited in: Adverse Effects and Toxicity
[79]
Dur Ş, Karadağ Aytemiz ÖE, Dinç S. “Comparative effectiveness of the Buzzy®, ShotBlocker® and Helfer skin tap technique in reducing pain and fear during pediatric intramuscular injections: A randomized controlled trial.” International emergency nursing (2026). PMID: 41512361 ↗
L1RCTCited in: Adverse Effects and Toxicity
[80]
Lee YJ, Raviraj A, Tsao H. “A rare case of lung hernia associated with rib fractures and tension pneumothorax post cardiopulmonary resuscitation.” The American journal of emergency medicine (2026). PMID: 41762556 ↗
L4CASE_REPORTCited in: Adverse Effects and Toxicity
[81]
Kumaraswamy M, Do C, Sakoulas G et al.. “Listeria monocytogenes endocarditis: case report, review of the literature, and laboratory evaluation of potential novel antibiotic synergies.” International journal of antimicrobial agents (2018). PMID: 29337066 ↗
L4CASE_REPORTCited in: Drug Interactions
[82]
Baburaj G, Thomas L, Rao M. “Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies.” Archives of medical research (2021). PMID: 33257051 ↗
L5REVIEW_NARRATIVECited in: Drug Interactions
[83]
Beganovic M, Luther MK, Rice LB et al.. “A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2018). PMID: 29390132 ↗
L5REVIEW_NARRATIVECited in: Drug Interactions
[84]
Yu X, Chu Z, Li J et al.. “Pharmacokinetic Drug-drug Interaction of Antibiotics Used in Sepsis Care in China.” Current drug metabolism (2021). PMID: 32990533 ↗
L5SR_OBSCited in: Drug Interactions
[85]
Luque Paz D, Cañas MA, Cuervo G et al.. “In vitro activity of amoxicillin combined with oral cephalosporins against endocarditis-associated E. faecalis clinical isolates.” The Journal of antimicrobial chemotherapy (2026). PMID: 41967057 ↗
L5OTHERCited in: Drug Interactions
[86]
Gonçalves IS, Soares JM, Bagnato VS et al.. “Targeting the Dynamic Susceptibility Window: Time-Sensitive Photodynamic Synergy With Antibiotics Against Streptococcus spp.” Lasers in surgery and medicine (2026). PMID: 41755426 ↗
L5OTHERCited in: Drug Interactions
[87]
Damaceno NdS, Freire NML, Sturaro MC et al.. “Synergistic effects of ceftriaxone combined with BLI-489 against NDM-producing Klebsiella pneumoniae.” Microbiology spectrum (2026). PMID: 41733354 ↗
L5OTHERCited in: Drug Interactions
[88]
Ashrin A, Hagenimana C, Jacquier H et al.. “Synergistic but clinically unattainable: amoxicillin/ceftriaxone combination against ampicillin-susceptible Enterococcus faecium.” The Journal of antimicrobial chemotherapy (2026). PMID: 41247078 ↗
L5OTHERCited in: Drug Interactions
[89]
Raffetin A, Roblot F, Lenormand C et al.. “Guidelines for Lyme borreliosis: treatment.” Infectious diseases now (2025). PMID: 41314469 ↗
L1GUIDELINECited in: Special Populations and Contraindications
[90]
Alhusseini LB, Chaki SSG, Noshak MA et al.. “Cell wall-inhibiting antibiotics resistance in Streptococcus pneumoniae causing invasive diseases: a global systematic review and meta-analysis in pediatric populations.” Italian journal of pediatrics (2025). PMID: 41430708 ↗
L2SR_OBSCited in: Special Populations and Contraindications
[91]
Armstrong J, Sriranjan J, Briatico D et al.. “Piperacillin/tazobactam versus ceftriaxone/metronidazole for children with perforated appendicitis: a systematic review and meta-analysis.” Pediatric surgery international (2025). PMID: 41186640 ↗
L2SR_OBSCited in: Special Populations and Contraindications
[92]
Skripai A, Katz A, Lellouche J et al.. “Emerging Ceftriaxone Resistance in Paediatric Shigella sonnei: A 10-Year Retrospective Study.” Acta paediatrica (Oslo, Norway : 1992) (2026). PMID: 41555678 ↗
L3COHORTCited in: Special Populations and Contraindications
[93]
Palma-Díaz EJ, Domínguez-Hermosillo JC, Tondopó-Guerrero J et al.. “Clinical and microbiological profile of invasive Salmonella disease in Mexico: a single-center retrospective study.” BMC infectious diseases (2025). PMID: 41455889 ↗
L3COHORTCited in: Special Populations and Contraindications

Quick Reference

Overview and Recommendations

Key Facts

Clinical Use

Safety

Board Review — High Yield

Deep Dive — Evidence Details

Introduction and Chemical Structure

Chemical Identity and Composition

Clinical Significance and Resistance

Mechanism of Action

Molecular Targets and Antimicrobial Cascade

Non-Antimicrobial Pharmacologic Effects

Immunomodulatory and Gut-Brain Axis Interactions

Controversies and Guideline Disagreement

Pharmacokinetics (LADME)

Distribution and Protein Binding

Metabolism and Dual Elimination

Pharmacokinetics in Special Populations

Controversies and Guideline Disagreement

Pharmacodynamics

Protein Binding and Free Fraction

Tissue-Specific Pharmacodynamics

Clinical Outcomes and Mortality Risks

Controversies and Guideline Disagreement

Indications and Clinical Use

Sexually Transmitted and Gastrointestinal Infections

Sepsis and Prophylactic Applications

Skin, Bone, and Intra-abdominal Infections

Controversies and Guideline Disagreement

Dose and Administration

Adult Dosing Regimens

Pediatric and Neonatal Considerations

Specific Infectious Protocols

Controversies and Guideline Disagreement

Dose Modification

Pediatric and High-Dose CNS Regimens

Organ Impairment and Critical Care

Neonatal Contraindications and Calcium Interactions

Controversies and Guideline Disagreement

Adverse Effects and Toxicity

Biliary and Renal Precipitation

Hypersensitivity and Cutaneous Reactions

Neurotoxicity and Hematologic Effects

Gastrointestinal and Local Effects

Controversies and Guideline Disagreement

Drug Interactions

Pharmacokinetic Interactions

Therapeutic Synergy

Controversies and Guideline Disagreement

Special Populations and Contraindications

Pediatrics

Pregnancy and Breastfeeding

Geriatric Use and Neurotoxicity

Controversies and Guideline Disagreement

References

Sexually Transmitted and Infections

and Local Effects

Pregnancy and